At the news
? NEUTRALIMPACT 2/10 144 filed Jun 30, 2026 at 16:13 ET
Director Jakob Dupont filed a Form 144 on June 30, 2026, indicating intent to sell 35,000 shares of Pyxis Oncology common stock, valued at approximately $107,034. The shares were acquired via a stock option exercise on the same day. This is a routine director sale following an option exercise and does not signal a change in company fundamentals.
- Director Jakob Dupont filed Form 144 to sell 35,000 shares of Pyxis Oncology common stock.
- Estimated sale value is approximately $107,034 based on the filing date.
- Shares were acquired via stock option exercise on June 30, 2026.
- The sale is to be executed through Fidelity Brokerage Services LLC.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access